Filters

Choose one market

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

United Arab Emirates

Federal registration and pricing are followed by different formulary, insurance, procurement and provider routes in Abu Dhabi, Dubai and the federal/northern-emirate systems.

EDE / MAH / licensed local applicant

EDE Pharmaceutical Pricing Committee / importer

company / payer / provider / patient

DoH Drug and Medical Products / HTA Taskforce

DoH / insurer or TPA / EHS or provider P&T and procurement

8 decision nodes15 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it

Evidence checked through 2026-08-06A pathway is a decision map—not a launch-time promise

Locate the relevant route first

These choices define how to read the branches below. They do not predict a payer or provider decision.

1

Which UAE jurisdiction and payer apply?Coverage rules and provider networks differ by emirate and plan.

Selected routeAbu Dhabi / DoH7 applicable nodes

Authorization-to-patient timeline

See the selected route reach the patient

Updates immediately when a choice changes

1

EDE marketing authorisationlawful pricing and supply

2

Emirate, payer, programme and setting selectorcoding/coverage or procurement

3

Abu Dhabi product coding and HTA scopeappraisal or direct coverage implementationSelected branch

4

Coverage, formulary or public-procurement decisionprovider/pharmacy execution

5

Provider/pharmacy contracting and stockpatient authorisation and treatment

6

Patient eligibility, prescription and prior authorisationdispense/administer and claim

7

First funded patientEligible patient + capable provider + authorization + product + clean payment

1Select emirate, payer and provider network

2Confirm federal label and price

3Secure formulary/insurance and contract

4Verify authorisation, procurement and stock

Do not collapse these decisions

Federal registration and official price do not create a DHA, DoH, insurer or hospital formulary decision.

Decision map

What each local node actually produces

Select a row to inspect legal effect and downstream gates

#Local decision / ownerDecision outputDownstream dependencyEvidence

Decision question

Does the exact product meet UAE quality, safety, efficacy, label and PV requirements?

Required evidence / materials

eCTD, registered MAH/manufacturer, licensed warehouse/manufacturer/marketing office, quality and PV material

Can iterate or branch

questions, requested stability/bioequivalence/analysis, variation, renewal or recall

Source date

AE-S01 · EDE established 2023-09-29；AE-S02 · current service

Node linked to cited dossier sourcesProduct/provider execution still requires live verification

Special mechanisms and lifecycle

What can reopen price, coverage or procurement after launch

Dates below come from the cited policy record—not a product forecast

Mechanism / triggerDecision outputIteration / branchPolicy recordLatest observed

Dispense/administer, claim and lifecycle controlpaid/adjusted/rejected claim and first funded patientpost-approval study, reassessment, repricing, new indication, shortage, PV/recall or exitAE-S05 · AE-S06 · AE-S08 · AE-S09 · AE-S13updated 2026-07-27

Price reviewFormulary/insurance renewalTender cycleNew indication and prior-authorisation change

Evidence & policy library

Official basis and policy dates

15 records · checked 2026-08-06